Cooley has participated in more than 380 offerings since 2000, raising more than $35.7 billion. Following are some recent representative offerings. Completed IPOs | ISSUER | OFFERING AMOUNT
(in millions) | DATE | | Epizyme, Inc.* | $77.1 | May 2013 | | ChannelAdvisor Corporation | $92.6 | May 2013 | | Portola Pharmaceuticals, Inc. | $140.4 | May 2013 | | Tableau Software, Inc. | $292.3 | May 2013 | | Ambit Biosciences Corporation | $65 | May 2013 | | Receptos, Inc.* | $72.8 | May 2013 | | Cyan, Inc.* | $88.0 | May 2013 | | Insys Therapeutics, Inc. | $36.8 | May 2013 | | Rally Software | $96.6 | April 2013 | | Chimerix, Inc. | $117.9 | April 2013 | | Gladstone Land Corporation | $45.6 | January 2013 | | LipoScience, Inc. | $51.8 | January 2013 | | Ruckus Wireless | $126.0 | November 2012 | | Ambarella, Inc.* | $41.4 | October 2012 | | Regulus Therapeutics Inc. | $50.9 | October 2012 | | LifeLock, Inc.* | $141.3 | October 2012 | | Qualys, Inc.* | $90.9 | September 2012 | | Peregrine Semiconductor Corporation* | $77.0 | August 2012 | | Hyperion Therapeutics, Inc.* | $57.5 | July 2012 | | ServiceNow, Inc.* | $241.2 | June 2012 | | Enphase Energy, Inc. | $53.8 | March 2012 | | Millenial Media, Inc. | $132.6 | March 2012 | | Vocera Communications, Inc.* | $107.6 | March 2012 | | Yelp | $123.3 | March 2012 | | Proto Labs, Inc.* | $79.1 | February 2012 | | Zynga Inc. | $1000.0 | December 2011 | | NewLink Genetics Corporation | $43.4 | November 2011 | | Horizon Pharma, Inc. | $49.5 | July 2011 | | Tangoe, Inc.* | $87.7 | July 2011 | | LinkedIn Corporation* | $405.7 | May 2011 | | AcelRx Pharmaceuticals, Inc. | $40.0 | February 2011 | | NeoPhotonics Corporation | $94.9 | February 2011 | | Epocrates, Inc. | $98.6 | February 2011 | | Trius Therapeutics, Inc. | $50 | August 2010 | | BroadSoft, Inc. | $67.5 | June 2010 | | Convio, Inc.* | $46.2 | April 2010 | | Calix* | $82.3 | March 2010 | | QuinStreet | $150 | February 2010 | *Represented the underwriters Completed Follow-On Offerings | ISSUER | OFFERING AMOUNT
(in millions) | DATE | | Acadia Pharmaceuticals Inc. | $115.0 | May 2013 | | Santarus, Inc.* | $89.2 | May 2013 | | Isis Pharmaceuticals, Inc. | $171.0 | May 2013 | | Anacor Pharmaceuticals, Inc. | $23.0 | April 2013 | | U.S. Auto Parts | $2.2 | March 2013 | | Cardica, Inc. | $15.0 | March 2013 | | Cerus Corporation | $40.2 | March 2013 | | Hyperion Therapeutics, Inc.* | $68.6 | March 2013 | | Jazz Pharmaceuticals | $314.4 | March 2013 | | NewLink Genetics Corporation | $52.4 | January 2013 | | Anthera Pharmaceuticals, Inc* | $46.0 | January 2013 | | Trius Therapeutics, Inc. | $11.3 | January 2013 | | Trius Therapeutics, Inc. | $23.1 | January 2013 | | Onyx Pharmaceuticals | $358.6 | January 2013 | | InterMune, Inc.* | $153.7 | January 2013 | | AcelRx Pharmaceuticals, Inc. | $41.4 | December 2012 | | DURECT Corporation* | $12.6 | December 2012 | | NovaBay Pharmaceuticals, Inc. | $7.4 | December 2012 | | Proto Labs, Inc.* | $128.3 | November 2012 | | ServiceNow, Inc.* | $392.0 | November 2012 | | Millennial Media, Inc. | $141.5 | October 2012 | | Xoma Corporation | $40.0 | October 2012 | | MannKind Corporation | $92.0 | October 2012 | | ImmunoCellular Therapeutics, Ltd | $21.0 | October 2012 | | Anacor Pharmaceuticals, Inc. | $27.6 | October 2012 | | Geron | $50.0 | October 2012 | | Rigel Pharmaceuticals, Inc. | $149.5 | October 2012 | | Horizon Pharma, Inc. | $81.1 | October 2012 | | Vocera Communications, Inc.* | $138.7 | September 2012 | | AcelRx Pharmaceuticals, Inc. | $7.5 | September 2012 | | Exelixis, Inc. | $146.6 | August 2012 | | MAP Pharmaceuticals, Inc.* | $59.8 | August 2012 | | XenoPort, Inc. | $46.0 | August 2012 | | Anthera Pharmaceuticals, Inc.* | $38.0 | July 2012 | | Arena Pharmaceuticals, Inc. | $69.6 | May 2012 | | PROLOR Biotech, Inc.* | $37.4 | May 2012 | | Dynavax Technologies Corporation | $55.0 | May 2012 | | Tangoe, Inc.* | $148.0 | March 2012 | | Zynga Inc. | $593.0 | March 2012 | | Amylin Pharmaceuticals, Inc. | $210.5 | March 2012 | | Jazz Pharmaceuticals Public Company Limited | $390.7 | March 2012 | | Arena Pharmaceuticals, Inc. | $24.9 | March 2012 | | Alexza Pharmaceuticals, Inc. | $22.0 | February 2012 | | Exelixis, Inc. | $69.6 | February 2012 | | Cardica, Inc. | $15.0 | February 2012 | | MannKind Corporation | $86.2 | February 2012 | | Ardea Biosciences, Inc. | $166.2 | February 2012 | | Trius Therapeutics, Inc. | $45.2 | January 2012 | | ZIOPHARM Oncology, Inc. | $62.0 | January 2012 | | Sequenom Inc. | $62.0 | January 2012 | | Neurocrine Biosciences, Inc. | $77.0 | January 2012 | | Vical, Inc. | $9.9 | January 2012 | | LinkedIn Corporation* | $714.4 | November 2011 | | Cadence Pharmaceuticals* | $81.8 | November 2011 | | Dynavax Technology | $69.4 | November 2011 | | Gladstone Capital Corporation | $38.5 | November 2011 | | InterMune, Inc.* | $96.0 | September 2011 | | GTx, Inc. | $47.5 | June 2011 | | Cerus Corporation | $20.0 | June 2011 | | Rigel Pharmaceuticals, Inc. | $150.0 | May 2011 | | Medicinova, Inc. | $15.0 | May 2011 | | Alexza Pharmaceuticals | $16.1 | May 2011 | | Arca Biopharma, Inc. | $3.0 | April 2011 | | Iridium Communications, Inc. | $32.9 | March 2011 | | Medicinova, Inc. | $8.3 | March 2011 | | Affymax, Inc. | $47.0 | March 2011 | | Exelexis, Inc. | $189.8 | March 2011 | | Opko Health, Inc.* | $110.2 | March 2011 | | Limelight Networks* | $81.7 | February 2011 | | Optimer Pharmaceuticals, Inc. | $77.6 | February 2011 | | ZIOPHARM Oncology, Inc.* | $55.2 | February 2011 | | Seattle Genetics, Inc. | $178.3 | February 2011 | | Corcept Therapeutics Incorporated* | $44.9 | January 2011 | | Ardea Biosciences, Inc. | $82.2 | January 2011 | | Nektar Therapeutics* | $225.2 | January 2011 | | Quidel Corporation* | $60.5 | January 2011 | | BroadSoft, Inc. | $116.6 | December 2010 | | Aastrom Biosciences, Inc.* | $22.5 | December 2010 | | XenoPort Inc. | $28.6 | December 2010 | | Sequenom Inc. | $96.6 | December 2010 | | Somaxon Pharmaceuticals, Inc.* | $26.0 | November 2010 | | Micromet, Inc. | $70.8 | November 2010 | | Cerus Corporation | $21.0 | November 2010 | | Cadenece Pharmaceuticals* | $100.0 | November 2010 | | Dynavax Technologies | $45.0 | October 2010 | | GTx, Inc. | $40.0 | October 2010 | | Anadys Pharmaceuticals, Inc. | $25.0 | October 2010 | | Cytori Therapeutics Inc.* | $20.7 | October 2010 | | Sunesis Pharmaceuticals, Inc. | $15.5 | October 2010 | | Entropic Communications | $104.3 | September 2010 | | Vical, Inc. | $33.8 | September 2010 | | Aspen Technology | $162.0 | September 2010 | | Radiant Systems* | $91.8 | September 2010 | | MannKind Corporation | $50.0 | August 2010 | | Alexza Pharmaceuticals | $18.0 | August 2010 | | Corcept Therapeutics Incorporated* | $15.0 | June 2010 | | Clinical Data | $27.8 | June 2010 | | ZIOPHARM Oncology, Inc.* | $35 | May 2010 | | Anadys Pharmaceuticals, Inc. | $12.5 | May 2010 | | RegeneRx BioPharmaceuticals, Inc. | $4.7 | May 2010 | | Jazz Pharmaceuticals | $58.5 | May 2010 | | Alphatec Holdings* | $80.0 | April 2010 | | Dynavax Technologies Corporation | $44.0 | April 2010 | | Ardea Biosciences | $70.0 | April 2010 | | Somaxon Pharmaceuticals, Inc.* | $49.5 | March 2010 | | Micromet, Inc. | $70.0 | March 2010 | | Neurocrine Biosciences, Inc. | $20.0 | March 2010 | | Optimer Pharmaceuticals | $46.8 | February 2010 | | Senomyx, Inc. | $20.0 | February 2010 | | Art Technology Groups, Inc.* | $87.5 | February 2010 | | AMAG Pharmaceuticals | $165.9 | January 2010 | | InterMune, Inc.* | $98.7 | January 2010 | *Represented the underwriters Completed Debt Securities/Preferred Stock Offerings | ISSUER | OFFERING AMOUNT
(in millions) | DATE | | OPKO Health, Inc.* | $175.0 | January 2013 | | Brocade Communications Systems | $300.0 | January 2013 | | InterMune, Inc.* | $120.8 | January 2013 | | Volcano Corporation | $460.0 | December 2012 | | Intarcia Therapeutics, Inc. | $50.0 | November 2012 | | Iridium Communications Inc. | $100.0 | September 2012 | | Sequenom, Inc. | $130.0 | September 2012 | | Isis Pharmaceuticals | $227.5 | August 2012 | | Exelixis, Inc. | $287.5 | August 2012 | | Medivation, Inc. | $258.8 | March 2012 | | PDL Biopharma* | $180.0 | January 2012 | *Represented the investment bank
|